

Cover Story
Free
An NCI-sponsored trial showed that up to 70 percent of women with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer would not benefit from chemotherapy.
In Brief
Funding Opportunities
Trending Stories
- Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - Tom Sellers steps down as director of OHSU Knight, replaced by Lisa Coussens
Shivaani Kummar recently named interim CEO - DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - In The Headlines: Private funding can’t replace federal funding—but it can help
- Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers